Molecular biomarkers in pediatric glial tumors: A needed wind of change

Current Opinion in Oncology

Volumn 25, Issue 6, 2013, Pages 665-673

  Fontebasso, Adam M ^a   Bechet, Denise ^b   Jabado, Nada ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

ATRX; BRAF; epigenome; histone 3; pediatric gliomas

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; HISTONE H3; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; VASCULOTROPIN RECEPTOR;

ASTROCYTOMA; BRAIN CORTEX; BRAIN STEM; CANCER GRADING; CANCER MORTALITY; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; COST EFFECTIVENESS ANALYSIS; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; FRONTAL LOBE; GENE CLUSTER; GENE DOSAGE; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA; HETEROCHROMATIN; HUMAN; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; NONHUMAN; OLIGODENDROGLIOMA; ONCOGENE; OVERALL SURVIVAL; PATHOGENESIS; PERSONALIZED MEDICINE; PHENOTYPE; PILOCYTIC ASTROCYTOMA; PONTINE GLIOMA; PREVALENCE; PRIORITY JOURNAL; PROTEIN PROCESSING; REPRESSOR GENE; REVIEW; SEX RATIO; TELOMERE; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; VIRUS ONCOGENE;

ADOLESCENT; ADULT; ASTROCYTOMA; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; EPIGENOMICS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MUTATION; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84885427226     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000007     Document Type: Review

References (79)

1. Central Brain Tumor Registry of the United States (CBTRUS) statistical report: primary brain and central nervous system tumors in the United States in 2004-2008. 23 March 2012 revision. http://www.cbtrus.org/2012-NPCR-SEER/CBTRUS- Report-2004-2008-3-23-2012.pdf. [Accessed 18 August 2012).
2. Bailey P, Cushing HA. A classification of the tumours of the glioma group on a histogenetic basis, with a correlated study of prognosis. Philadelphia: J. B. Lippincott; 1926.
3. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114:97-109.
4. Wohrer A, Waldhor T, Heinzl H, et al. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 2009; 95:401-411.
5. Kieran MW, Walker D, Frappaz D, Prados M. Brain tumors: from childhood through adolescence into adulthood. J Clin Oncol 2010; 28:4783-4789.
6. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-1812.
7. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765-773.
8. Lai A, Kharbanda S, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 2011; 29:4482-4490.
9. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
10. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27:5743-5750.
11. Bourne TD, Schiff D. Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol 2010; 6:695-701.
12. Ohgaki H, Kleihues P. Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 2011; 28:177-183.
13. Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011; 333:1453-1455.
14. Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 2012; 226:7-16.
15. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblas-toma. Am J Pathol 2007; 170:1445-1453.
16. Peraud A, Kreth FW, Wiestler OD, et al. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 2002; 8:1117-1124.
17. The Tumor Cancer Genome Atlas (TCGA) Project. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061-1068.
18. Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst 2001; 17:503-511.
19. Fontebasso AM, Liu XY, Sturm D, Jabado N. Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail. Brain Pathol 2013; 23:210-216.
20. Broniscer A, Baker SJ, West AN, et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol 2007; 25:682-689.
21. Rood BR, Macdonald TJ. Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches. J Neurooncol 2005; 75:267-272.
22. Listernick R, Charrow J, Gutmann DH. Intracranial gliomas in neurofibroma-tosis type 1. Am J Med Genet 1999; 89:38-44.
23. Pollack IF, Mulvihill JJ. Neurofibromatosis 1 and 2. Brain Pathol 1997; 7:823-836.
24. Stokland T, Liu JF, Ironside JW, et al. A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol 2010; 12:1257-1268.
25. Fernandez C, Figarella-Branger D, Girard N, et al. Pilocytic astrocytomas in children: prognostic factors-a retrospective study of 80 cases. Neurosur-gery 2003; 53:544-553; discussion 54-55.
26. Fisher PG, Tihan T, Goldthwaite PT, et al. Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer 2008; 51:245-250.
27. Gajjar A, Sanford RA, Heideman R, et al. Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital. J Clin Oncol 1997; 15:2792-2799.
28. Ishii N, Sawamura Y, Tada M, et al. Absence of p53 gene mutations in a tumor panel representative of pilocytic astrocytoma diversity using a p53 functional assay. Int J Cancer 1998; 76:797-800.
29. Cheng Y, Pang JC, Ng HK, et al. Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas. Histopathology 2000; 37:437-444.
30. Tada K, Kochi M, Saya H, et al. Preliminary observations on genetic alterations in pilocytic astrocytomas associated with neurofibromatosis 1. Neuro Oncol 2003; 5:228-234.
31. Pfister S, Witt O. Pediatric gliomas. Recent Results Cancer Res 2009; 171:67-81.
32. Qaddoumi I, Sultan I, Gajjar A. Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database. Cancer 2009; 115:5761-5770.
33. Forshew T, Tatevossian RG, Lawson AR, et al. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2009; 218:172-181.
34. Jacob K, Albrecht S, Sollier C, et al. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer 2009; 101:722-733.
35. Jones DT, Kocialkowski S, Liu L, et al. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009; 28:2119-2123.
36. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008; 68:8673-8677.
37. Pfister S, Janzarik WG, Remke M, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008; 118:1739-1749.
38. Sievert AJ, Jackson EM, Gai X, et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol 2009; 19:449-458.
39. Janzarik WG, Kratz CP, Loges NT, et al. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics 2007; 38:61-63.
40. Sharma MK, Zehnbauer BA, Watson MA, Gutmann DH. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology 2005; 65:1335-1336.
41. Maltzman TH, Mueller BA, Schroeder J, et al. Ras oncogene mutations in childhood brain tumors. Cancer Epidemiol BiomarkersPrev 1997;6:239-243.
42. Eisenhardt AE, Olbrich H, Roring M, et al. Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer 2011; 128:2297-2303.
43. Yu J, Deshmukh H, Gutmann RJ, et al. Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology 2009; 73:1526-1531.
44. Cin H, Meyer C, Herr R, et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 2011; 121:763-774.
45. Zhang J, Wu G, Miller CP, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 2013; 45:602-612.
46. Jones DT, Hutter B, Jager N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013; 31:2927-2935.
47. Singh D, Chan JM, Zoppoli P, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012; 337:1231-1235.
48. Jones DT, Gronych J, Lichter P, et al. MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci 2012; 69:1799-1811.
49. Hawkins C, Walker E, Mohamed N, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 2011; 17:4790-4798.
50. Jacob K, Quang-Khuong DA, Jones DT, et al. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clin Cancer Res 2011; 17:4650-4660.
51. Sievert AJ, Lang SS, Boucher KL, et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A 2013; 110:5957-5962.
52. Rusconi P, Caiola E, Broggini M. RAS/RAF/MEK inhibitors in oncology. Curr Med Chem 2012; 19:1164-1176.
53. Ramkissoon LA, Horowitz PM, Craig JM, et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rear rangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A 2013; 110:8188-8193.
54. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009; 4:e7887.
55. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1, 320 nervous system tumors reveals high mutation frequencies in pleo-morphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic as-trocytoma. Acta Neuropathol 2011; 121:397-405.
56. Fontebasso AM, Schwartzentruber J, Khuong-Quang DA, et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol 2013; 125:659-669.
57. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 2012; 124:439-447.
58. Liu XY, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012; 124:615-625.
59. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012; 482:226-231.
60. Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and nonbrainstem glioblastomas. Nat Genet 2012; 44:251-253.
61. Heaphy CM, deWilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011; 333:425.
62. Lewis PW, Elsaesser SJ, Noh KM, et al. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci U S A 2010; 107:14075-14080.
63. Drane P, Ouararhni K, Depaux A, et al. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev 2010; 24:1253-1265.
64. Goldberg AD, Banaszynski LA, Noh KM, et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 2010; 140:678-691.
65. Wong LH, McGhie JD, Sim M, et al. ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Res 2010; 20:351-360.
66. Downing JR, Wilson RK, Zhang J, et al. The Pediatric Cancer Genome Project. Nat Genet 2012; 44:619-622.
67. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012; 22:425-437.
68. Roberts CW, Biegel JA. The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther 2009; 8:412-416.
69. Edmunds JW, Mahadevan LC, Clayton AL. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J 2008; 27:406-420.
70. Venneti S, Garimella MT, Sullivan LM, et al. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. J Neuropathol Exp Neurol 2013; 72:298-306.
71. Lewis PW, Muller MM, Koletsky MS, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013; 340:857-858.
72. Chan KM, Fang D, Gan H, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 2013; 27:985-990.
73. Bjerke L, Mackay A, Nandhabalan M, et al. Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov 2013; 3:512-519.
74. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget 2012; 3:709-722.
75. Kannan K, Inagaki A, Silber J, et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 2012; 3:1194-1203.
76. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483:474-478.
77. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19:17-30.
78. Sasaki M, Knobbe CB, Munger JC, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012; 488:656-659.
79. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of aCpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17:510-522.